FDA & Government News

FDA Okays Weekly Option in Achondroplasia

Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.

Share

The FDA has approved navepegritide (YUVIWEL) to enhance linear growth in pediatric patients aged 2 years and above with achondroplasia and open epiphyses, based on clinical trial data showing improved annualized growth velocity. This condition, caused by a fibroblast growth factor receptor 3 variant, leads to various complications including spinal abnormalities and reduced muscle strength. Navepegritide operates through continuous systemic exposure to counteract overactive receptor signaling. Approval is granted with the expectation of further confirmatory trials.

Original Source(s)

FDA Okays Weekly Option in Achondroplasia

Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.

  • by Kathryn Wighton

  • March 2, 2026

  • 2 min

Related Content

Youth Obesity Reaches 20% in US

New data from over 6 million children reveal persistent weight disparities across age and racial groups.

Unusual Neonatal Presentation of 48,XXYY

Dual presentation expands known phenotypic spectrum of the syndrome

Vaccine Playbook Rewrite: Who’s In Charge?

HHS Secretary Robert F. Kennedy Jr.’s changes at the CDC are prompting states and medical societies to issue independent vaccine recommendations, challenging long-standing national immunization policy.